• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Wave Life Sciences Ltd. - Ordinary Shares (NQ:WVE)

    6.615 +0.415 (+6.69%)
    Streaming Delayed Price Updated: 12:36 PM EDT, Mar 27, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Wave Life Sciences Ltd. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    News headline image
    Stock Market Today, March 26: Wave Life Sciences Plunges After High Dose Obesity Drug Data Disappoints ↗
    On March 26, 2026, traders mulled Wave's weak high-dose obesity results against the company's large market opportunity. 
    Via The Motley Fool
    Topics Stocks
    Top movers analysis one hour before the close of the markets on 2026-03-26: top gainers and losers in today's session. ↗
    Via Chartmill
    Here are the top movers in Thursday's session. ↗
    Via Chartmill
    Thursday's session: gap up and gap down stocks ↗
    Via Chartmill
    Wave Life Sciences Ltd (NASDAQ:WVE) Reports Mixed Q4 2025 Results, Highlights Extended Cash Runway to 2028 ↗
    Via Chartmill
    The 2025 Weight-Loss Drug Gold Rush: How Eli Lilly Pulled Ahead, Novo Hit A Snag — And A Swarm Of Biotech Underdogs Are Closing In ↗
    Via Stocktwits
    News headline image
    Wave Life Sciences Shakes Biotech Sector with Breakthrough Obesity Data: A New Era for ‘Quality’ Weight Loss
    The biotechnology landscape witnessed a defining moment on March 26, 2026, as Wave Life Sciences (Nasdaq: WVE) released highly anticipated interim Phase 1 data from its INLIGHT trial. The study, which... 
    Via MarketMinute
    These stocks that are showing activity before the opening bell on Thursday. ↗
    Via Chartmill
    News headline image
    Wave Life Sciences Announces Positive Interim Phase 1 Data from INLIGHT: Further Improvements in Body Composition, with Clinically Meaningful Reductions in Visceral Fat and Waist Circumference, at Six Months Following Single Dose of WVE-007
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    News headline image
    Wave Life Sciences Announces Acceptance of Late-Breaking Oral Presentation on WVE-006 for Alpha-1 Antitrypsin Deficiency at the American Thoracic Society International Conference
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    News headline image
    Wave Life Sciences (WVE) Earnings Call Transcript ↗
    Wave Life Sciences (WVE) Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Wave Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    News headline image
    Wave Life Sciences to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    News headline image
    Wave Life Sciences Fourth Quarter and Full Year 2025 Financial Results Scheduled for February 26, 2026
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    News headline image
    Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
    From BioMedWire
    Via GlobeNewswire
    News headline image
    Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    News headline image
    This Director Sold 42,000 Shares of Wave Life Sciences for $630,000. What Investors Should Know About This Biotech Company. ↗
    This biotech innovator in genetic medicines reported significant insider selling, as disclosed in recent SEC filings. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Wave Life Sciences Highlights Strategic Priorities for 2026 at the 44th Annual J.P. Morgan Healthcare Conference: Accelerating Development of WVE-007 (INHBE siRNA) for Obesity and Rapidly Advancing RNA Editing Portfolio
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    Stay updated with the stocks that are on the move in today's pre-market session. ↗
    Via Chartmill
    News headline image
    Wave Life Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    In today's session, these stocks are experiencing unusual volume. 
    Via Chartmill
    News headline image
    Golden Cross Alert: 3 Stocks With Major Upside Potential ↗
    Via MarketBeat
    News headline image
    Wave Life Sciences Prices Upsized $350 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    News headline image
    Why Wave Life Sciences Stock Crushed it Again Today ↗
    There's nothing like a nearly 150% price gain to garner the attention of investors and analysts. 
    Via The Motley Fool
    News headline image
    Which stocks have an unusual volume on Tuesday? ↗
    Discover the stocks with unexpected trading volume in today's session on the US markets. 
    Via Chartmill
    News headline image
    ENDRA Life Sciences (NASDAQ: NDRA) Advances TAEUS® Liver Imaging, Strengthens Capital Efficiency; WVE, TWG, BDRX, FULC Also Active
    Via AB Newswire
    News headline image
    Why Structure Therapeutics Stock Doubled and Then Some on Monday ↗
    The company's investigational GLP-1 treatment performed admirably well in a phase 2b study. 
    Via The Motley Fool
    News headline image
    Why Wave Life Sciences Stock Vaulted 146% Higher on Monday ↗
    We have an emerging new entrant in the increasingly crowded weight loss drug space. 
    Via The Motley Fool
    Biggest Stock Movers Today, Dec. 8: CFLT, UL, & More ↗
    Via The Motley Fool
    News headline image
    Wave Life Sciences Announces Proposed $250 Million Public Offering of Ordinary Shares and Pre-Funded Warrants
    From Wave Life Sciences USA, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.